AMGN stock verdict - Avoid
AMGN
Amgen Inc.
AVOIDHealthcare
$414.61
Fundamentals below bar
$414.61
Heavy$298.76Buy$398.34Fair$497.93Exit$597.52
VALUE50
GROWTH25
QUALITY100
TECHNICAL—
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Trades 17% below the model's fair value ($497.93)
- Strong return on equity of 74.8% (TTM)
- Revenue grew 11.9%/yr on average over the last 3 years
- TTM EPS grew 88.2% year-over-year
- Balance sheet holds net cash (cash exceeds total debt)
CONS
- High leverage — debt-to-equity of 4.61
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 143% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on AMGN. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is AMGN rated Avoid?
AMGN (Amgen Inc.) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Trades 17% below the model's fair value ($497.93) and Strong return on equity of 74.8% (TTM)
Is AMGN overvalued right now?
AMGN is trading at $414.61 versus an estimated fair value of $497.93. That puts the stock in avoid territory on this framework. High leverage — debt-to-equity of 4.61
What should I watch before acting on AMGN?
Watch the trust score of 100, the earnings-quality checks, and any red flags. High leverage — debt-to-equity of 4.61